# Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-empagliflozin-added-to-existing-antidiabetes-treatment-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Anthony Barnett,Ambrish Mithal,Jenny Manassie,Russell Jones,Henning Rattunde,Hans J. Woerle,Uli C. Broedl |
| Citations | 576 |
| DOI | 10.1016/s2213-8587(13)70208-0 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2152413054 |
| PMID | 24795251 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Uli C. Broedl](https://scholariq.org/researchers/uli-c-broedl/)

## Paper journal

- [The Lancet Diabetes & Endocrinology](https://scholariq.org/journals/the-lancet-diabetes-and-endocrinology/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.